摘要:
The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one lipid lowering compound used to treat dyslipidaemia, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a medicament.
摘要:
The present invention relates to compounds having pharmacological activity towards the 5-HT 7 receptor, especially as agonists, identified by using a pharmacophore and a descriptor's profile filter as well as to pharmaceutical compositions comprising them. These compounds are useful in therapy in particular for the treatment and or prophylaxis of a disease in which 5-HT 7 is involved, such as CNS disorders.
摘要:
The present invention relates to heterocyclyl-substituted-ethylamino-phenyl compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans or animals
摘要:
The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.
摘要:
A process is described for the preparation of a precursor alcohol of (±)-2-[thienyl(1-methyl-1 H -pyrazol-5-yl)methoxy]- NN -dimethyletanamine and in general for thyenylazolylalcoxyethanamines and their enantiomers. It comprises the asymmetric addition of a metalated thienyl reagent to a pyrazolcarbaldehyde in the presence of a chiral ligand to render chiral alcohols. The chiral alcohols are further O-alkylated to render the corresponding pharmaceutically active thyenylazolylalcoxyethanamines.
摘要:
The present invention refers to the use of compounds binding to the sigma receptor for the treatment or prevention of neuropathic pain resulting from chemotherapy.
摘要:
The present invention relates to substituted tetrahydroisoquinoline compounds of general formula I,
a process for their preparation, medicaments comprising said substituted tetrahydroisoquinoline compounds as well as the use of said substituted tetrahydroisoquinoline compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via 5-HT 6 receptors.
摘要:
The present invention relates to compounds having pharmacological activity towards the 5-HT 7 receptor; to a method for identifying them as 5-HT 7 ligands, especially as agonists, by using a pharmacophore and a descriptor's profile filter; to pharmaceutical compositions comprising them; and to their use in therapy, in particular for the treatment and or prophylaxis of a disease in which 5-HT 7 is involved, such as CNS disorders.
摘要:
A process is described for the preparation of a precursor alcohol of (±)-2-[thienyl(1-methyl-1 H -pyrazol-5-yl)methoxy]- N , N dimethyletanamine and in general for thyenylazolylalcoxyethanamines and their enantiomers. It comprises the asymmetric reduction of a prochiral ketone in the presence of a chiral ruthenium (II) catalyst system comprising at least a bidentate phosphorous-containing ligand and a diamine ligand to render chiral alcohols. The chiral alcohols are further O-alkylated to render the corresponding pharmaceutically active ethanamines.